Senzime launches the next generation TOF-monitor, TetraGraph

Uppsala, November 11, 2016. Market introduction of TetraGraph @ Medica 

Every year over 70 million surgical patients undergo general anesthesia combined with muscle relaxant drugs. Without objective monitoring about 30 percent of these patients suffer postoperative complications. TetraGraph is Senzimes unique objective patient monitoring system that enables the correct dose of muscle relaxant drugs to be given and indicates when the patient can be brought out of its general anesthesia; factors that contribute to less complications, better care experience and reduces costs.

Senzime is co-exhibiting with Business Sweden in Hall1 D20, please book a meeting with us!

Link to a film about TetraGraph 

(See picture in PDF)

For further information, please contact:
Catrin Molund, Business Development Director
Tel: +46 708-11 69 111, email: catrin.molund@senzime.com 

TO THE EDITORS 

About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of $10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI) www.senzime.com